Merck's Gardasil is the only one FDA-approved for use in males as well as females; GlaxoSmithKline's Cervarix is approved for girls and women.
It has been a week of conciliation among some of the Big Pharma players, with Pfizer settling more Chantix litigation, Merck closing out some Vioxx lawsuits and Johnson & Johnson coming to terms with shareholders angered over its handling of Tylenol recalls.
The Palo Alto, CA-based company scored $30.6 million in a Series B round of financing from a deep-pocketed crowd that includes Citi Ventures, GE Ventures as well as returning backers Khosla Ventures and Floodgate.
Merck's struggling R&D group has been hit with yet another delay in its long and costly quest to gain an FDA approval for sugamaddex.
A new paper has validated the Centers for Disease Control and Prevention's 2011 recommendation that males receive the HPV vaccine, particularly men who have sex with men, who are a higher risk group.
Merck's Phase Ib dose-escalating study for MK-8931, a BACE inhibitor for Alzheimer's, has demonstrated a positive effect in reducing the level of toxic proteins flowing through patients, securing Merck's leading position in the BACE-inhibition crowd.
Chinese regulators say they will size up the cost structures and pricing of 60 drugmakers, both domestic and foreign, as it figures out what it should be paying for drugs.
Fretting over the potential for serious side effects, the FDA has batted aside Merck's ($MRK) application to sell the new insomnia drug suvorexant, demanding that the pharma giant substitute a significantly weaker dose than the company had wanted to sell.
Last Thursday, Merck & Co sold off a Netherlands-based API plant to Aspen Pharmacare, with the latter company looking to expand its manufacturing operations in Europe. Merck, however, might be relieved to contract its own operations in that particular corner of the continent, as the plant is part of an inherited manufacturing network that began causing the company grief when it tried to slash jobs there in 2010.
For Aspen Pharmacare, the purchase of a Netherlands-based API plant from Merck & Co. was just a piece of a European expansion strategy that has recently taken flight. But for Merck, the sale meant saving some jobs at an inherited plant that was part of labor controversy in years past.